الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 16 |  |  |
| | | from | 16 | | |
Abstract
Carcinoma of the breast is the most prevalent cancer among females worldwide. It constitutes 29% of National Cancer Institute cases in Cairo.
Breast cancer is the second leading cause of cancer death for women in U.S. after lung cancer and is the leading cause of death among women in West Africa.
Early breast cancer includes stage 0, stage IA, stage IB, stage IIA, stage IIB .
Diagnosis of early breast cancer depends on early detection and screening. Breast physical examination and mammography is the corner stone in detection specially in high risk patient.
Early detection of breast cancer leads to changing the concept of management in different aspect including changing the concept of radical mastectomy into conservative surgery which includes wider excision and axillary L.N. evacuation.
Also the concept of sentinel L.N. biopsy reduced the risk of axillary evacuation including lymphoedema.
Recent advances in molecular classification of breast malignancy includes luminal A, luminal B, normal breast like tumors, HER2 amplified and basal (triple negative ). This changes the bases of application of adjuvant systemic treatment.
Introduction of anti-HER2 neu-protein as a target in all cases of early breast cancer more than 0.5 c.m. lesion and HER2 new score III is included in all international guidelines.
More confined localized field of radiotherapy is one of the most challenging issues in treatment of early cases. partial breast irradiation, conformal radiotherapy,IMRT, brachytherapy are examples for these recent modalities.
The mamma print assay is the first fully commercialized microarray-based multigene assay designed to individualize treatment for patients with breast cancer . It is offered as a prognostic test for women under age 61 years with either estrogen receptor-positive or negative, lymph node-negative breast cancer .